Funder
Cure Cancer Australia Foundation
Cancer Australia
National Health and Medical Research Council (AU)
Cancer Institute NSW
Canadian Institutes of Health Research (CA)
Multiple Sclerosis Research Australia (AU)
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference62 articles.
1. Kong Y, Kumar SM, Xu X. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med. 2010;134(12):1740–9.
2. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012;26(11):1131–55.
3. Wilkins DK, Nathan PD. Therapeutic opportunities in noncutaneous melanoma. Ther Adv Med Oncol. 2009;1(1):29–36.
4. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14. doi: 10.1056/NEJMoa1203421 .
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in Metastatic melanoma. N Engl J Med. 2010;363(9):809–19. doi: 10.1056/NEJMoa1002011 .
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献